Bristol Myers Squibb Co. (BMY) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

|

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

Follow our journey and product updates

Product

Research a topic Stock screener Find companies Search for securities Load an existing portfolio Backtest

Learn

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices Build investment strategies with crypto

Company

How to use About us Blog

Team Research

There is currently no saved research for this page.

Bristol Myers Squibb Co. (BMY)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Company performance

Add to research

Current Price

as of Mar 21, 2025

$61.07

P/E Ratio

N/A

Market Cap

$123.93B

Description

Add to research

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Metrics

Add to research

Overview

HQPrinceton, NJ
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerBMY
Price$61.07+1.08%

Trading Information

Market cap$123.93B
Float99.92%
Average Daily Volume (1m)13,257,619
Average Daily Volume (3m)11,227,021
EPS-$4.41

Company

Revenue$48.30B
Rev growth (1yr)7.32%
Net income-$8.95B
Gross margin56.80%
EBITDA margin39.98%
EBITDA$19.31B

EV$155.04B
EV/Revenue3.21
P/EN/A
P/S2.54
P/B7.50
Debt/Equity313.44

Documents

Add to research

SEC Filings

8-K (2025-02-18)

8-K (2025-02-06)

8-K (2025-01-13)

8-K (2024-10-31)

8-K (2024-07-26)

8-K (2024-06-18)

8-K (2024-05-09)

8-K (2024-04-25)

8-K (2024-03-18)

8-K (2024-02-22)

8-K (2024-02-15)

8-K (2024-02-14)

8-K (2024-02-02)

8-K (2024-01-08)

8-K (2023-12-22)

8-K (2023-11-13)

8-K (2023-10-26)

8-K (2023-08-10)

8-K (2023-07-27)

8-K (2023-05-04)

8-K (2023-04-27)

8-K (2023-04-26)

8-K (2023-02-28)

8-K (2023-02-02)

8-K (2023-01-31)

8-K (2023-01-09)

10-Q (2024-10-31)

10-Q (2024-07-26)

10-Q (2024-04-25)

10-Q (2023-10-26)

10-Q (2023-07-27)

10-Q (2023-04-27)

10-K (2025-02-12)

10-K (2024-02-13)

10-K (2023-02-14)

Factset Street Account

StreetAccount Metrics Recap - Bristol Myers Squibb Q3 Earnings ($56.61, 0.00) (2023-10-26T11:04:31Z)

StreetAccount Earnings Call Q&A Summary: Bristol Myers Squibb Q3 ($56.61, 0.00) (2023-10-26T13:43:31Z)

StreetAccount Consensus Metrics Preview - Bristol Myers Squibb Q3 Earnings ($56.46, 0.00) (2023-10-23T16:17:34Z)

FDA approves sBLA for Opdivo as adjuvant treatment for melanoma ($56.47, 0.00) (2023-10-13T22:12:45Z)

EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Naveruclif (2023-11-10T12:43:35Z)

EMA valicates Bristol Myers Squibb application for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy for the first-line treatment of adult patients with Unresectable or Metastatic Urothelial Carcinoma ($51.02, 0.00) (2023-10-30T11:00:42Z)

Bristol Myers Squibb upgraded to hold from reduce at HSBC ($52.97, 0.00) (2023-10-27T10:21:56Z)

Bristol Myers Squibb to present new data at the American Heart Association Scientific Sessions 2023 ($52.82, 0.00) (2023-11-06T12:04:44Z)

Bristol Myers Squibb reports Q3 non-GAAP EPS $2.00 vs FactSet $1.76 [20 est, $1.67-1.87] ($56.61, 0.00) (2023-10-26T11:03:41Z)

Bristol Myers Squibb downgraded to neutral from overweight at Cantor Fitzgerald ($50.52, 0.00) (2023-11-15T11:12:45Z)

Bristol Myers Squibb downgraded to market perform from outperform at William Blair ($52.97, 0.00) (2023-10-27T09:09:22Z)

Bristol Myers Squibb downgraded to hold from outperform at Daiwa ($51.28, 0.00) (2023-11-02T12:17:13Z)

Bristol Myers Squibb announces three-year follow-up results from exploratory analyses of the Phase 3 CheckMate -816 trial ($57.29, +0.11) (2023-10-17T19:54:36Z)

Bristol Myers Squibb announces presentation of research across hematology and cell therapy portfolio and pipeline at ASH 2023 ($50.99, -0.29) (2023-11-02T15:40:30Z)

Bristol Myers Squibb announces highlighted data to be presented at ESMO 2023 ($56.65, 0.00) (2023-10-12T11:22:09Z)

Bristol Myers Squibb announces first presentation of results from the Phase 3 CheckMate -901 trial ($57.30, +0.13) (2023-10-17T19:52:13Z)

Bristol Myers Squibb announces FDA Breakthrough Therapy Designation for BMS-986278 ($56.00, 0.00) (2023-10-24T11:01:46Z)

Bristol Myers Squibb announces FDA accepts for priority review application for Breyanzi (lisocabtagene maraleucel) for relapsed or refractory CLL or SLL ($51.79, -0.64) (2023-11-09T15:16:12Z)

Bristol Myers Squibb announced the first disclosure of data from the Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy ($57.33, +0.16) (2023-10-17T19:28:06Z)

Wikipedia

Bristol_Myers_Squibb_Co.

Earnings Calls

Earnings Report 2024Q4

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-10-26)

Earnings Report (2023-07-27)

Factset

Factset Business Description

Ask a question

New feature

Thematic Research

View all of your research in one place. Toggle open the floating actions menu and click Open research sidebar to view your saved research for the current page.